SimBioSys
  • Home
  • Technology
  • Solutions
    • TUMORSIGHT PLAN
    • TUMORSIGHT IQ
    • PHENOSCOPE

      CLINICAL SOLUTIONS

      • TumorSight Plan
      • TumorSight IQ

      RESEARCH SOLUTIONS

      • PhenoScope
  • Resources
  • About Us
    • Our Company
    • Our Team
    • Careers
      • Our Company
      • Our Team
      • Careers
Contact Us

Month: December 2022

admin December 20, 2022 SABCS 2022

Validation of prognostic platform to further refine identification High Risk Patients indicated for Chemotherapy Free Treatment in Early-Stage Breast Cancer

We used a novel 2-paramenter pharmacokinetic modeling framework that allows biosignatures to be extracted from dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) studies that contain 3-6 timepoints spaced 60-90 seconds apart. These parameters, referred to as P1 and P2,…

Continue
admin December 20, 2022 SABCS 2022

Development of a Novel Imaging Biomarker to Ascertain Responsiveness to Immunotherapy

Currently, a lack of tests to differentiate patients likely to respond to IO vs. poor responders precludes a tailored approach to immunotherapy. Here we describe an imaging biomarker that allows physicians to target breast cancer patients with the highest likelihood…

Continue
admin December 20, 2022 SABCS 2022

A 3D Visualization and Prediction Device for Breast Cancer Surgeons and their Patients

Despite chemotherapeutic advances, surgery remains a putative treatment modality for breast cancer. The type of surgery chosen, and its ultimate clinical and cosmetic consequences, depends on a surgeon’s ability to accurately assess a tumor’s size, distribution, and position in the…

Continue
admin December 20, 2022 SABCS 2022

A 3D Visualization Method for Breast Cancer Surgeons and Patients

In order to accurately evaluate the potential success of various surgical options, a surgeon must mentally translate these 2D images into more realistic, 3D image to visualize breast and tumor morphologies.

Continue
admin December 20, 2022 SABCS 2022

Independent validation of a novel, non-invasive approach to predict pathologic complete response (pCR) in a blinded, prospectively-run single center trial

We developed the TumorScope engine, a software platform that utilizes pretreatment diagnostic data to build a computational tumor model that simulates in vivo tumor characteristics and interactions, incorporating morphology, metabolism, vascularity, and nutrient and drug delivery.

Continue
admin December 20, 2022 SABCS 2022

pCR Score: A Novel Prognostic Method to Estimate the Predictive Probability of pCR in Early-Stage Breast Cancer Patients.

To drive further utility, we now investigate a pCR score as a continuous outcome (0-100) to establish a prognostic system that evaluates the predictive probability that a patient will achieve pCR with any SOC NAT regimen.

Continue
admin December 20, 2022 SITC 2022

T-cell metabolic activity is impacted by the nutrient composition within the tumor microenvironment

Our results demonstrated that the local nutrient composition has a dramatic impact on T cell functionality, with fundamental cellular behaviors being significantly impaired by a reduction in key nutrients such as glucose and oxygen.

Continue
admin December 20, 2022 SITC 2022

The Next Generation of Immunotherapy Response Signatures Revealed by Biophysical Simulations

Here, we present a proof-of-concept approach for the rapid, non-invasive assessment of immunotherapy response prediction using biomarker imaging signatures.

Continue
admin December 20, 2022 ACoP13, Publications

Biophysical simulation approach for dose escalation in Phase I clinical trials

Here we performed a proof-of-concept study using trastuzumab emtansine (TDM1), a targeted drug for HER2-enriched breast cancer, to demonstrate how biophysical modeling can support dose selection in phase I clinical trials.

Continue
admin December 14, 2022 Blogs

Harnessing the immune system to develop breakthrough cancer therapies

The last decade in cancer care has been defined by the rapid emergence (and in some cases, dominance), of monoclonal antibody therapies, where they serve as a critical foundation of oncologic care.

Continue

Recent Posts

  • Highlights from ESMO 2022
  • Radiologist validation of a multi-tissue breast segmentation convolutional neural net ensemble
  • DCE-MRI-derived microvasculature mapping and outcome prediction in patients with breast cancer.
  • Association of biophysics-based biomarker with tumor volumetric response in breast cancer treated with immunotherapy.
  • Next generation immuno-oncology tumor profiling using a biophysics-based biomarker to predict immunotherapy response in early-stage breast cancer

Recent Comments

No comments to show.

Archives

  • November 2023
  • June 2023
  • December 2022
  • October 2022
  • September 2022
  • June 2022
  • May 2022
  • April 2022
  • December 2021
  • October 2021
  • May 2021
  • March 2021
  • October 2020
  • May 2020
  • March 2020
  • February 2020
  • January 2019
  • November 2018
  • October 2018
  • September 2017
  • August 2017
  • June 2017
  • March 2017
  • November 2016
  • June 2016
  • December 2015
  • October 2015
  • July 2015
  • March 2015
  • May 2014
  • February 2013

Categories

  • AACR 2022
  • AACR 2023
  • Abstracts
  • ACoP13
  • Articles
  • ASCO 2020
  • ASCO 2021
  • ASCO 2022
  • ASCO 2023
  • Blogs
  • Cell NCI Symposium 2021
  • ESMO Breast Cancer 2022
  • ISMRM 2023
  • Life science boxes
  • News
  • Podcast
  • Press Releases
  • Publications
  • SABCS 2019
  • SABCS 2021
  • SABCS 2022
  • Scientific Papers
  • SITC 2022
  • Whitepaper
SimBioSys

SOLUTIONS

  • TumorSight Plan
  • TumorSight IQ
  • PhenoScope

RESOURCES

  • Publications
  • Abstracts
  • White Papers
  • Press Releases
  • News
  • Blogs
  • Articles

ABOUT

  • Technology
  • Our Company
  • Our Team
  • Careers
  • Contact Us

LEGAL

  • Terms of Service
  • Privacy Policy

©SimBioSys